Biomolecular Pharma Inc

Biomolecular Pharma, Inc. is an innovative company developing pharmaceutical agents. The company is on the leading edge of investigations associated with the vast amounts of accumulated data on molecular structures and creative use of information regarding chemical molecules and biological macromolecules. The strategic scientific direction is focused on designing novel candidate pharmacologic agents for a wide range of disorders including primary brain cancers, multiple sclerosis, various viral infections, as well as other neurological diseases.

News

The drugs are in process of being manufactured under FDA requirements.

For Immediate Release: December 18, 2008

Mount Allison adjunct professor makes advances in multiple sclerosis research

SACKVILLE, NB - Dr. William G. Tucker, an adjunct professor at Mount Allison University and the President of Biomolecular Pharma Inc., has made what he thinks is a startling discovery with the potential to give people suffering from multiple sclerosis (MS) hope for an improved life.

Dr. Tucker developed the " MS " drug while at Henry Ford Hospital.

Based on successful testing of seven patients at the Henry Ford Hospital, Dr. Tucker is certain that stopping the replication of this virus can stabilize and prevent further neurologic progression in the MS patient. He says, "This drug, which is only effective in treating multiple sclerosis, augments the work of the patient's own immune system. A patient's antibodies control the virus, with the help of our new anti-viral drug, putting the MS into a quiescent stage. The drug, in effect, creates a constant block against viral cell division. At the first onset of neurological degeneration, a lumbar puncture can be done to test for the measles virus. At that time, and the sooner the better, the MS can be treated."

The drug, which has no side effects and is non-toxic, will stop progression of the neurologic symptoms of MS, with improvements in motor, sensory, and visual functions. Vivian Tucker, the vice-president of Biomolecular Pharma Inc., says, "This drug gives people their lives back. It is as simple and as effective as that. We stopped the drug at six months with no recurrence of disease."

Many researchers in the past have called MS an autoimmune disease, but Dr. Tucker, an oncologist who has practised medicine and taught in the oncology department at the Henry Ford Hospital in Detroit Michigan, believes that there are many reasons to attribute MS, instead, to the measles virus. They are calling this the multiple sclerosis measles virus (MSMV). MS is prevalent in northern and southern climates but is virtually absent at the equator. This, among other features, rules out autoimmune disorders as a cause for MS in his mind. There are, however, a number of additional reasons that Dr. Tucker is convinced that the MSMV is the root cause of MS.

Measles virus antibodies are found in the confined closed organ system (CSF) of all MS patients. This is the only viral antibody found in all MS patients. Also, says Dr. Tucker, "MV antibodies are significantly higher in the CSF of MS patients than in control groups. The measles virus does not cross the blood brain barrier since it is too large but it enters through the olfactory nerve root, causing demyelination and damage to the epithelial cells lining the capillaries. Without a myelin sheath, nerves stop functioning."

The clinical pilot study of seven patients had complete arrest of the disease (cure) with no recurrence.

The drug has been patented but the company will require funding to get it to market and into the hands of pharmaceutical companies. The clinical study was originally published in 1969 in the Henry Ford Hospital Medical Journal.